Patient characteristics: the CAP-Centre study
| Total | Death at 1 year | SCLC | Resected NSCLC | Unresected NSCLC | |
| Subjects n | 685 | 331 | 113 | 106 | 466 |
| General characteristics | |||||
| Male | 496 (72.4) | 254 (51.2) | 88 (77.9) | 72 (67.9) | 336 (72.1) |
| Age years, median (interquartile range) | 66.0 (59–73) | 65.0 (60–74) | 66.0 (60–72) | 67.0 (58–74) | |
| Performance status score | |||||
| 0–1 | 565 (82.5) | 233 (41.2) | 90 (79.6) | 104 (98.1) | 371 (79.6) |
| 2 | 85 (12.4) | 65 (76.5) | 18 (15.9) | 2 (1.9) | 65 (13.9) |
| 3–4 | 35 (5.1) | 33 (94.3) | 5 (4.5) | 30 (6.5) | |
| Histology, n=662 | |||||
| Adenocarcinoma | 311 (47.6) | 138 (44.4) | 54 (56.2) | 257 (57.9) | |
| Undifferentiated carcinoma | 62 (9.5) | 38 (61.3) | 9 (9.4) | 53 (11.9) | |
| Squamous cell carcinoma | 149 (22.8) | 70 (47.0) | 30 (31.2) | 119 (26.8) | |
| Others | 50 (7.3) | 10 (55.5) | 13 (12.2) | 37 (7.9) | |
| SCLC | 113 (17.3) | 67 (59.3) | 113 (100) | ||
| Disease stage, n=531 | |||||
| I | 29 (5.4) | 2 (6.9) | 1 (1.2) | 26 (38.8) | 2 (0.5) |
| II | 27 (5.1) | 3 (11.1) | 2 (2.4) | 21 (31.3) | 4 (1.0) |
| III | 72 (13.5) | 23 (31.9) | 5 (6) | 13 (19.5) | 54 (14.2) |
| IV | 403 (75.9) | 253 (62.8) | 75 (90.4) | 7 (10.4) | 321 (84.3) |
| First healthcare facility | |||||
| Administrative department | |||||
| A | 49 (7.2) | 27 (55.1) | 5 (4.4) | 6 (5.7) | 38 (8.2) |
| B | 87 (12.7) | 58 (66.7) | 23 (20.4) | 9 (8.5) | 55 (11.8) |
| C | 38 (5.5) | 21 (55.3) | 9 (8) | 5 (4.7) | 24 (5.2) |
| D | 265 (38.7) | 111 (41.9) | 36 (31.9) | 45 (42.5) | 184 (39.5) |
| E | 40 (5.8) | 20 (50.0) | 6 (5.3) | 7 (6.6) | 27 (5.8) |
| F | 174 (25.4) | 81 (46.5) | 28 (24.8) | 25 (23.6) | 121 (26) |
| Outside of CVL region | 32 (4.7) | 13 (40.6) | 6 (5.3) | 9 (8.5) | 17 (3.6) |
| Nature | |||||
| Teaching hospital | 203 (29.6) | 96 (47.3) | 29 (25.7) | 31 (29.2) | 143 (30.7) |
| Public hospital | 223 (32.6) | 135 (60.5) | 49 (43.4) | 24 (22.6) | 150 (32.2) |
| Private Hospital | 259 (37.8) | 100 (38.6) | 35 (31.0) | 51 (48.1) | 173 (37.1) |
| Driving time min | |||||
| 00–14 | 187 (27.4) | 101 (54.0) | 36 (31.9) | 21 (19.8) | 130 (28.0) |
| 15–25 | 153 (22.5) | 74 (48.4) | 29 (25.7) | 23 (21.7) | 101 (21.8) |
| 25–45 | 153 (22.5) | 71 (46.4) | 22 (19.5) | 24 (22.6) | 107 (23.1) |
| ≥45 | 188 (27.6) | 84 (44.7) | 25 (22.1) | 37 (34.9) | 126 (27.1) |
| First treatment | |||||
| Therapeutic abstention | 136 (19.9) | 123 (90.4) | 23 (20.3) | 113 (24.2) | |
| Resection | 99 (14.5) | 12 (12.1) | 3 (2.7) | 96 (90.6) | |
| Targeted therapy | 27 (3.9) | 10 (37.0) | 27 (5.8) | ||
| Immunotherapy | 60 (8.8) | 26 (43.3) | 1 (0.9) | 59 (12.7) | |
| Chemotherapy | 329 (48.0) | 148 (45.0) | 83 (73.5) | 9 (8.5) | 237 (50.9) |
| Radiotherapy | 30 (4.4) | 11 (36.7) | 3 (2.7) | 27 (5.8) | |
| Radio-chemotherapy | 4 (0.6) | 1 (25) | 1 (0.9) | 3 (0.6) | |
| Case-fatality | |||||
| Death at 1 year | 331 (48.3) | 67 (59.3) | 13 (12.3) | 251 (53.9) | |
Data presented as n (%) unless indicated otherwise. SCLC: small cell lung cancer; NSCLC: nonsmall cell lung cancer; CVL: Centre-Val de Loire.